Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
21
INCPF Quote, Financials, Valuation and Earnings
Last price:
$1.55
Seasonality move
:
0%
Day range:
$1.55 - $1.55
52-week range:
$1.55 - $3.26
Dividend yield:
0%
P/E ratio:
30.10x
P/S ratio:
8.22x
P/B ratio:
2.47x
Volume:
--
Avg. volume:
133
1-year change:
-52.45%
Market cap:
$2.7B
Revenue:
$328.1M
EPS (TTM):
$0.05
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INCPF
InnoCare Pharma Ltd.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -- | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$116.5M | -$0.48 | 10.78% | -4.05% | $38.47 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INCPF
InnoCare Pharma Ltd.
|
$1.55 | -- | $2.7B | 30.10x | $0.00 | 0% | 8.22x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
VBIZF
Viva Biotech Holdings
|
$0.3434 | -- | $724.5M | 16.20x | $0.00 | 1.01% | 3.33x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
$8.96 | -- | $18.6B | 27.92x | $0.00 | 0% | 6.24x |
|
ZLAB
Zai Lab Ltd.
|
$20.41 | $38.47 | $2.3B | -- | $0.00 | 0% | 4.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INCPF
InnoCare Pharma Ltd.
|
17.25% | 1.013 | 6.38% | 5.67x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.237 | 12.91% | 11.22x |
|
VBIZF
Viva Biotech Holdings
|
24.82% | 1.403 | -- | 1.26x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
5.93% | 2.689 | -- | 1.98x |
|
ZLAB
Zai Lab Ltd.
|
23.86% | 0.688 | 11.48% | 2.18x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INCPF
InnoCare Pharma Ltd.
|
$164.8M | $94M | 7.65% | 9.4% | 52.89% | $25.3M |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -1.17% | -1.8% | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | 7.16% | 7.53% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$65.6M | -$69.7M | -17.96% | -22.45% | -54.4% | -$19.1M |
InnoCare Pharma Ltd. vs. Competitors
-
Which has Higher Returns INCPF or SVA?
Sinovac Biotech Ltd. has a net margin of 56.86% compared to InnoCare Pharma Ltd.'s net margin of --. InnoCare Pharma Ltd.'s return on equity of 9.4% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital INCPFInnoCare Pharma Ltd.92.77% $0.06 $1.3B SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About INCPF or SVA?
InnoCare Pharma Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that InnoCare Pharma Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe InnoCare Pharma Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings INCPFInnoCare Pharma Ltd.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is INCPF or SVA More Risky?
InnoCare Pharma Ltd. has a beta of 0.176, which suggesting that the stock is 82.446% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.313%.
-
Which is a Better Dividend Stock INCPF or SVA?
InnoCare Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. InnoCare Pharma Ltd. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios INCPF or SVA?
InnoCare Pharma Ltd. quarterly revenues are $177.6M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. InnoCare Pharma Ltd.'s net income of $101M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, InnoCare Pharma Ltd.'s price-to-earnings ratio is 30.10x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InnoCare Pharma Ltd. is 8.22x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INCPFInnoCare Pharma Ltd.8.22x 30.10x $177.6M $101M SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns INCPF or VBIZF?
Viva Biotech Holdings has a net margin of 56.86% compared to InnoCare Pharma Ltd.'s net margin of --. InnoCare Pharma Ltd.'s return on equity of 9.4% beat Viva Biotech Holdings's return on equity of -1.8%.
Company Gross Margin Earnings Per Share Invested Capital INCPFInnoCare Pharma Ltd.92.77% $0.06 $1.3B VBIZFViva Biotech Holdings-- -- $694.7M -
What do Analysts Say About INCPF or VBIZF?
InnoCare Pharma Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Viva Biotech Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that InnoCare Pharma Ltd. has higher upside potential than Viva Biotech Holdings, analysts believe InnoCare Pharma Ltd. is more attractive than Viva Biotech Holdings.
Company Buy Ratings Hold Ratings Sell Ratings INCPFInnoCare Pharma Ltd.0 0 0 VBIZFViva Biotech Holdings0 0 0 -
Is INCPF or VBIZF More Risky?
InnoCare Pharma Ltd. has a beta of 0.176, which suggesting that the stock is 82.446% less volatile than S&P 500. In comparison Viva Biotech Holdings has a beta of 0.650, suggesting its less volatile than the S&P 500 by 34.961%.
-
Which is a Better Dividend Stock INCPF or VBIZF?
InnoCare Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viva Biotech Holdings offers a yield of 1.01% to investors and pays a quarterly dividend of $0.00 per share. InnoCare Pharma Ltd. pays -- of its earnings as a dividend. Viva Biotech Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INCPF or VBIZF?
InnoCare Pharma Ltd. quarterly revenues are $177.6M, which are larger than Viva Biotech Holdings quarterly revenues of --. InnoCare Pharma Ltd.'s net income of $101M is higher than Viva Biotech Holdings's net income of --. Notably, InnoCare Pharma Ltd.'s price-to-earnings ratio is 30.10x while Viva Biotech Holdings's PE ratio is 16.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InnoCare Pharma Ltd. is 8.22x versus 3.33x for Viva Biotech Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INCPFInnoCare Pharma Ltd.8.22x 30.10x $177.6M $101M VBIZFViva Biotech Holdings3.33x 16.20x -- --
-
Which has Higher Returns INCPF or WXXWY?
WuXi Biologics (Cayman), Inc. has a net margin of 56.86% compared to InnoCare Pharma Ltd.'s net margin of --. InnoCare Pharma Ltd.'s return on equity of 9.4% beat WuXi Biologics (Cayman), Inc.'s return on equity of 7.53%.
Company Gross Margin Earnings Per Share Invested Capital INCPFInnoCare Pharma Ltd.92.77% $0.06 $1.3B WXXWYWuXi Biologics (Cayman), Inc.-- -- $6.6B -
What do Analysts Say About INCPF or WXXWY?
InnoCare Pharma Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand WuXi Biologics (Cayman), Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that InnoCare Pharma Ltd. has higher upside potential than WuXi Biologics (Cayman), Inc., analysts believe InnoCare Pharma Ltd. is more attractive than WuXi Biologics (Cayman), Inc..
Company Buy Ratings Hold Ratings Sell Ratings INCPFInnoCare Pharma Ltd.0 0 0 WXXWYWuXi Biologics (Cayman), Inc.0 0 0 -
Is INCPF or WXXWY More Risky?
InnoCare Pharma Ltd. has a beta of 0.176, which suggesting that the stock is 82.446% less volatile than S&P 500. In comparison WuXi Biologics (Cayman), Inc. has a beta of 0.020, suggesting its less volatile than the S&P 500 by 98.002%.
-
Which is a Better Dividend Stock INCPF or WXXWY?
InnoCare Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. WuXi Biologics (Cayman), Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InnoCare Pharma Ltd. pays -- of its earnings as a dividend. WuXi Biologics (Cayman), Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INCPF or WXXWY?
InnoCare Pharma Ltd. quarterly revenues are $177.6M, which are larger than WuXi Biologics (Cayman), Inc. quarterly revenues of --. InnoCare Pharma Ltd.'s net income of $101M is higher than WuXi Biologics (Cayman), Inc.'s net income of --. Notably, InnoCare Pharma Ltd.'s price-to-earnings ratio is 30.10x while WuXi Biologics (Cayman), Inc.'s PE ratio is 27.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InnoCare Pharma Ltd. is 8.22x versus 6.24x for WuXi Biologics (Cayman), Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INCPFInnoCare Pharma Ltd.8.22x 30.10x $177.6M $101M WXXWYWuXi Biologics (Cayman), Inc.6.24x 27.92x -- --
-
Which has Higher Returns INCPF or ZLAB?
Zai Lab Ltd. has a net margin of 56.86% compared to InnoCare Pharma Ltd.'s net margin of -39.51%. InnoCare Pharma Ltd.'s return on equity of 9.4% beat Zai Lab Ltd.'s return on equity of -22.45%.
Company Gross Margin Earnings Per Share Invested Capital INCPFInnoCare Pharma Ltd.92.77% $0.06 $1.3B ZLABZai Lab Ltd.51.15% -$0.46 $939.8M -
What do Analysts Say About INCPF or ZLAB?
InnoCare Pharma Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $38.47 which suggests that it could grow by 88.47%. Given that Zai Lab Ltd. has higher upside potential than InnoCare Pharma Ltd., analysts believe Zai Lab Ltd. is more attractive than InnoCare Pharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings INCPFInnoCare Pharma Ltd.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is INCPF or ZLAB More Risky?
InnoCare Pharma Ltd. has a beta of 0.176, which suggesting that the stock is 82.446% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.859, suggesting its less volatile than the S&P 500 by 14.084%.
-
Which is a Better Dividend Stock INCPF or ZLAB?
InnoCare Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InnoCare Pharma Ltd. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INCPF or ZLAB?
InnoCare Pharma Ltd. quarterly revenues are $177.6M, which are larger than Zai Lab Ltd. quarterly revenues of $128.2M. InnoCare Pharma Ltd.'s net income of $101M is higher than Zai Lab Ltd.'s net income of -$50.6M. Notably, InnoCare Pharma Ltd.'s price-to-earnings ratio is 30.10x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InnoCare Pharma Ltd. is 8.22x versus 4.87x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INCPFInnoCare Pharma Ltd.8.22x 30.10x $177.6M $101M ZLABZai Lab Ltd.4.87x -- $128.2M -$50.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
